Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Procrit Market CAGR Analysis And Future Market Development
The expansion observed in the historical period is linked to a higher incidence of chronic kidney disease, a growing number of chemotherapy-induced anemia cases, the uptake of biologic therapies for anemia, more dialysis treatment centers being established, and enhanced availability of prescribed anemia medications.
The anticipated expansion during the forecast period is driven by a growing emphasis on tailored anemia treatments, heightened uptake of biosimilar options, the broadening of chronic disease management initiatives, a stronger focus on improving patient well-being, and greater funding for biologic drug enhancements. Key developments shaping this period encompass the broader application of erythropoiesis-stimulating agents, escalating demand for therapies to address anemia, the advancement of supportive care in oncology, increased efforts to minimize blood transfusions, and more diligent oversight of persistent anemia cases.
Download A Free Sample Report For Comprehensive Market Insights:
Procrit Market Expansion Drivers: What Is Shaping Future Growth?
The growing prevalence of anemia is anticipated to boost the procrit market in the coming period. Anemia is defined as a medical disorder involving a shortage of healthy red blood cells or hemoglobin, which impairs oxygen delivery to bodily tissues. Its rising occurrence is driven by factors like the escalating global burden of chronic illnesses such as kidney failure, cancer, and inflammatory conditions, along with poor dietary habits that lead to deficiencies in iron, vitamin B12, and folate. Procrit (epoetin alfa) is employed in the management of anemia resulting from chronic kidney disease, chemotherapy, or certain HIV treatments. It functions by promoting red blood cell generation, thus lessening the necessity for blood transfusions in patients with low hemoglobin levels. For example, in December 2024, the National Center for Health Statistics, a U.S. government agency, reported that the prevalence of anemia among individuals aged 2 years and older in 2023 had risen by 9.3% compared to 2021. Consequently, the increasing occurrence of anemia is propelling the procrit market forward.
An increase in the prevalence of chronic kidney diseases is expected to drive expansion in the procrit market moving forward. Chronic kidney disease involves the progressive deterioration of kidney function, diminishing their capacity to filter blood waste. Its rising prevalence stems from factors like aging populations, obesity, lifestyle choices, and environmental exposures. Procrit (epoetin alfa) is administered to chronic kidney disease patients to address anemia by stimulating red blood cell production, thereby aiding in maintaining appropriate hemoglobin levels and decreasing the reliance on blood transfusions. As an illustration, a report from Kidney Research UK, a nonprofit organization based in the United Kingdom, released in June 2023, indicated that approximately 7.2 million people in the UK currently have chronic kidney disease, which constitutes over 10% of the population. Among these, 3.25 million are in advanced stages, while 3.9 million are in early stages. This figure is projected to climb to 7.61 million by 2033. Therefore, the heightened prevalence of chronic kidney diseases is fueling growth in the procrit market.
The escalating incidence of cancer is projected to propel the procrit market in the foreseeable future. Cancer encompasses a variety of diseases marked by the abnormal and uncontrolled proliferation of cells that can infiltrate and harm healthy tissues, potentially resulting in death if untreated. Its rising frequency is linked to factors such as an aging population, heightened exposure to risks like tobacco use, obesity, and environmental contaminants, evolving lifestyles, and enhanced diagnostic techniques that facilitate earlier and more precise detection. Procrit (epoetin alfa) is utilized in cancer patients receiving chemotherapy to address anemia by enhancing red blood cell production, boosting energy levels, and minimizing the need for blood transfusions. For instance, a report published in August 2024 by the Australian Institute of Health and Welfare, a national agency for health and welfare statistics in Australia, projected that by 2034, Australia will see approximately 209,000 new cancer diagnoses, a notable rise from the estimated 169,000 cases in 2024, driven by population growth and increasing cancer rates. Furthermore, in 2024, cancer is expected to account for roughly 3 out of every 10 deaths in the country. Hence, the growing incidence of cancer is stimulating demand in the procrit market.
Procrit Market Segment Breakdown: Which Categories Generate The Most Revenue?
The procrit market covered in this report is segmented –
1) By Indications: Chronic Kidney Diseases, Human Immunodeficiency Virus (HIV) Infection, Chemotherapy
2) By Distribution Channel: Direct Sales, Pharmaceutical Wholesalers, Retail Pharmacies
3) By End Users: Hospitals, Outpatient Clinics, Home Care
Procrit Market Key Players And Strategic Industry Positioning
Major companies operating in the procrit market are Amgen Inc.
Access The Complete Procrit Market Report:
Procrit Market Geographic Analysis: Where Is Demand Growing The Fastest?
North America was the largest region in the procrit market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the procrit market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model